PRKACB and Cognitive impairment: They found that madecassoside, one of the two major active constituents of ECa 233, enhanced learning and memory behavior and up-regulation of PSD-95, p-NMDAR1 (NR1 subunit), p-CaMKII, p-PKACβ, p-CREB and BDNF in the cognitive-impairment model27.